OMCL:NGS-Omnicell Inc. (USD)

EQUITY | Health Information Services | Nasdaq Global Select

Last Closing

USD 44.58

Change

+1.38 (+3.19)%

Market Cap

USD 1.28B

Volume

0.32M

Analyst Target

USD 81.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Omnicell Inc provides automation and business analytics software solutions for patient-centric medication and supplies management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
GEHC GE HealthCare Technologies Inc..

-0.20 (-0.25%)

USD 37.81B
HQY HealthEquity Inc

-1.11 (-1.14%)

USD 8.82B
TEM Tempus AI, Inc. Class A Common..

-0.17 (-0.48%)

USD 7.92B
WAY Waystar Holding Corp. Common S..

-0.25 (-0.65%)

USD 4.47B
BTSG BrightSpring Health Services, ..

-0.58 (-3.30%)

USD 3.18B
PRVA Privia Health Group Inc

-0.31 (-1.54%)

USD 2.52B
PINC Premier Inc

+0.05 (+0.23%)

USD 2.08B
WGS GeneDx Holdings Corp.

-1.40 (-1.76%)

USD 2.03B
GDRX Goodrx Holdings Inc

+0.10 (+2.21%)

USD 1.87B
CERT Certara Inc

-0.16 (-1.47%)

USD 1.75B

ETFs Containing OMCL

NIXT Research Affiliates Delet.. 1.08 % 0.00 %

-0.29 (-1.09%)

USD 0.04B
ROBO Robo Global® Robotics an.. 0.00 % 0.00 %

-0.40 (-1.09%)

USD 1.09B
ROBO Robo Global® Robotics an.. 0.00 % 0.95 %

-0.40 (-1.09%)

USD 1.09B
SBB ProShares Short SmallCap6.. 0.00 % 0.95 %

+0.19 (+-1.09%)

N/A
SDD ProShares UltraShort Smal.. 0.00 % 0.95 %

+0.47 (+-1.09%)

N/A
DMRS 0.00 % 0.45 %

N/A

N/A
IJR:AU iShares Core S&P SmallCap.. 0.00 % 0.00 %

+1.90 (+-1.09%)

USD 0.54B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.47% 77% C+ 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.47% 75% C 70% C-
Trailing 12 Months  
Capital Gain 14.72% 74% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.72% 74% C 68% D+
Trailing 5 Years  
Capital Gain -45.94% 63% D 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.94% 63% D 26% F
Average Annual (5 Year Horizon)  
Capital Gain -1.37% 58% F 35% F
Dividend Return -1.37% 58% F 31% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 61.52% 29% F 32% F
Risk Adjusted Return -2.23% 59% D- 33% F
Market Capitalization 1.28B 86% B+ 79% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Information Services) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 158.60 8% 3%
Price/Book Ratio 1.73 55% 55%
Price / Cash Flow Ratio 11.77 37% 26%
Price/Free Cash Flow Ratio 38.73 15% 10%
Management Effectiveness  
Return on Equity -1.46% 76% 57%
Return on Invested Capital -2.03% 67% 51%
Return on Assets -0.87% 65% 53%
Debt to Equity Ratio 47.91% 44% 42%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector